✦ LIBER ✦

Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study

✍ Scribed by Stocchi, Fabrizio; Hersh, Bonnie P.; Scott, Burton L.; Nausieda, Paul A.; Giorgi, Luigi

Book ID: 121293472
Publisher: Informa plc
Year: 2008
Tongue: English
Weight: 195 KB
Volume: 24
Category: Article
ISSN: 0300-7995
DOI: 10.1185/03007990802387130

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Steady-state pharmacokinetic properties

Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson's disease

✍ Debra J. Tompson; Deborah Vearer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 219 KB

Rotigotine transdermal patch in early Pa

Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole

✍ Nir Giladi; Babak Boroojerdi; Amos D. Korczyn; David J. Burn; Carl E. Clarke; An 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

## Abstract Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine,

Onset of dyskinesia with adjunct ropinir

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease

✍ Ray L. Watts; Kelly E. Lyons; Rajesh Pahwa; Kapil Sethi; Matthew Stern; Robert A 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Levodopa-induced dyskinesia can result in significant functional disability and reduced quality of life in patients with Parkinson's disease (PD). The goal of this study was to determine if the addition of once-daily ropinirole 24hour prolonged-release (n 5 104) in PD patients not optimally controll

The efficacy and safety of ropinirole pr

The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: A multicenter, double-blind, randomized, placebo-controlled study

✍ Zhang, Zhenxin; Wang, Jian; Zhang, Xiaoying; Chen, Shengdi; Wang, Zhenfu; Zhang, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 318 KB

2.242 Relationship between Unified Parki

2.242 Relationship between Unified Parkinson's disease Rating Scale total motor score and systemic exposure of ropinirole 24-hour prolonged release in patients with early stage Parkinson's disease

✍ D. Tompson; F. Stocchi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Corrigendum to “The efficacy and safety

Corrigendum to “The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: A multicenter, double-blind, randomized, placebo-controlled study” [Parkinsonism and Related Disorders 19 (2013) 1022–1026]

✍ Zhang, Zhenxin; Wang, Jian; Zhang, Xiaoying; Chen, Shengdi; Wang, Zhenfu; Zhang, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 147 KB